Nusinersen (Spinraza)
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease caused by loss-of-function mutations in the SMN1 gene, which encodes the survival motor neuron (SMN) protein. SMN protein is essential for motor neuron survival. Without sufficient SMN, motor neurons in the spinal cord degenerate, causing progressive muscle weakness and atrophy. SMA ranges from severe infantile onset (Type 1, the most common form) to milder adult-onset forms (Type 4).
Humans carry a nearly identical backup gene called SMN2. However, SMN2 has a single nucleotide difference in exon 7 (a C-to-T transition) that causes most transcripts to skip exon 7 during splicing. The resulting truncated protein is unstable and rapidly degraded. SMN2 produces only about 10–15% of the full-length SMN protein that SMN1 would produce. SMA severity correlates inversely with SMN2 copy number — more copies of SMN2 mean more residual SMN protein and milder disease.
This biology creates a perfect target for antisense oligonucleotide therapy. An ASO can be designed to bind a specific intronic splicing silencer (ISS-N1) in SMN2 pre-mRNA, blocking the signal that causes exon 7 exclusion. With the silencer masked, the splicing machinery includes exon 7, producing full-length, functional SMN protein from the SMN2 gene.
Nusinersen (Spinraza), approved by the FDA in December 2016, is the landmark ASO drug based on this mechanism. It was the first FDA-approved treatment for SMA and demonstrated that antisense oligonucleotides can meaningfully change the course of a genetic disease. Spinraza is a 2′-O-methoxyethyl (2′-MOE) phosphorothioate ASO administered by intrathecal injection. Clinical trials showed significant improvement in motor function and survival in infants with SMA Type 1.
Spinraza’s success is central to the ASO field because it proved several principles: that ASOs can reach motor neurons via intrathecal delivery, that modulating splicing can rescue a genetic deficiency, and that early treatment produces the best outcomes. It is one of the clearest validations that antisense technology works in humans.
While Spinraza targets a specific site in SMN2 that is common to all SMA patients (making it a universal rather than personalized treatment), the splice-switching principle it established applies broadly to other genetic diseases where aberrant splicing causes disease. For SMA patients specifically, Pequliar’s validation suite confirms that the platform recovers the Spinraza target sequence in blind testing — reproducing in minutes the discovery that took years of academic research.
For other diseases that share the splice-switching mechanism — where an ASO can correct defective splicing to restore functional protein — Pequliar designs patient-specific ASO candidates using the same thermodynamic and sequence-design principles that underlie Spinraza, adapted to the individual patient’s gene and mutation.
Describe your mutation and get ranked, synthesis-ready ASO candidates in minutes. $399 per design.
Start a designPequliar is a computational research tool for informational purposes only. All sequences are computationally predicted candidates that have not been experimentally validated. Pequliar does not prescribe, recommend, or administer any compound. Independent validation by qualified professionals is required.